AzTrials
AzTrials

Brain and Central Nervous System TumorsPhase 1NCT01233492

Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme

A Phase 1 study testing boron phenylalanine, mannitol and biologic sample preservation procedure in people with Brain and Central Nervous System Tumors, run by Cancer Research UK at 2 sites in United Kingdom.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as boron neutron capture therapy, for patients in the future. Read more about this study

Who is it for?
Ages 45 to 75 years
Conditions the study is for
Brain and Central Nervous System Tumors
What is being tested?
boron phenylalanine, mannitol and biologic sample preservation procedure
Type of treatment
Surgery or procedure
How many people
36 participants
Where
2 sitesUnited Kingdom
Study dates
Oct 2007to Sep 2013
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

DISEASE CHARACTERISTICS:

  • Radiologically and clinically suspected solitary glioblastoma multiforme
  • High-grade disease
  • Agreed to undergo stereotactic biopsy as part of routine diagnostic work-up

PATIENT CHARACTERISTICS:

  • WHO performance status 0-2 (0-1 for patients ≥ 65 years old)
  • Life expectancy > 4 months
  • Hemoglobin ≥ 9.0 g/dL
  • Neutrophil count ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Serum bilirubin ≤ 1.5 times upper normal of limit (ULN)
  • AST ≤ 1.5 times ULN
  • Uncorrected EDTA-Isotope creatinine clearance ≥ 40 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use two forms of effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy
  • Able to cooperate with procedures and follow-up
  • Not at high risk of complications from blood-brain barrier disruption with mannitol on pre-treatment CT scan (an open quadrigeminal plate cistern, absence of dilatation of the contralateral frontal horn, and absence of uncal herniation)
  • No history of uncontrolled seizures
  • No phenylketonuria
  • No current or previous malignancies at sites other than the brain, except for adequately treated cone-biopsied carcinoma in-situ of the uterine cervix or basal cell or squamous cell carcinoma of the skin
  • Not at high medical risk due to nonmalignant systemic disease, including active uncontrolled infection
  • No known hepatitis B, hepatitis C, or HIV positivity by serology
  • No concurrent congestive heart failure, history of NYHA class III-IV cardiac disease, history of myocardial infarction or active ischemic heart disease within the past year, or history of cardiac arrhythmia or thromboembolic disease
  • No other condition that, in the investigator's opinion, would not make the patient a good candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

  • At least 12 hours since prior and no concurrent steroids
  • At least 48 hours since prior phenylalanine-containing drinks (e.g., colas)
  • At least 48 hours since prior excessive consumption of phenylalanine-containing foods, including any of the following:
  • Low phenylalanine content (e.g., fruit juice, fruits [except bananas], vegetables, and low-protein breads and pastas
  • Medium phenylalanine content (e.g., corn, bread, french fries, potatoes, peas, rice, and regular pasta)
  • High phenylalanine content (e.g., refried beans, chicken, nuts, hamburgers, peanuts, cheese, eggs, pork chops, steak, bananas, and milk)
  • At least 4 weeks since prior major thoracic and/or abdominal surgery and recovered
  • No prior cranial radiotherapy
  • No prior endocrine therapy, immunotherapy, or chemotherapy for the brain tumor
  • No other concurrent anticancer therapy or investigational drugs

Trial locations and contacts

2 sites in 1 country.

United Kingdom2 sites
  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

    Birmingham, England, B15 2TH

  • Cancer Research UK Clinical Trials Unit - Birmingham

    Birmingham, England, B15 2TT

Other trials in United Kingdom

About this study

Official title: A Cancer Research UK Pharmacokinetic Study of BPA in Patients With High Grade Glioma to Optimize Uptake Parameters for Clinical Trials of BNCT

RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as boron neutron capture therapy, for patients in the future.

PURPOSE: This phase I trial is studying the side effects, best dose boron phenylalanine, and best way of giving it with or without mannitol in treating patients with glioblastoma multiforme.

Read the detailed description

OBJECTIVES:

Primary

  • To determine the optimal way to deliver boron phenylalanine (BPA) with or without mannitol in terms of route (intravenous vs intraarterial), blood-brain barrier disruption, and dose for use in subsequent therapeutic trials of boron neutron capture therapy (BNCT) in patients with high-grade glioma.
  • To evaluate the toxicity profile of BPA administered intravenously or intra-arterially.
  • To evaluate the pharmacokinetic behavior of BPA using samples of blood, urine, tumor tissue, normal brain tissue, extracellular fluid, and cerebrospinal fluid.

Secondary

  • To produce indicative treatment plans using BPA administered either intravenously or intra-arterially with or without mannitol to support the design of combination studies using BPA and thermal neutrons for BNCT.

Tertiary

  • To evaluate the micro-distribution of boron resulting from the different routes of administration using secondary ion mass spectroscopy (SIMS).
  • To store surplus tissues removed during the trial for possible future studies.

OUTLINE: This is a dose-escalation study.

  • Stage 1 (Route and Blood Brain Barrier Disruption [BBBD]): Patients receive one dose of boron phenylalanine intravenously (IV) or intra-arterially (IA) over 2 hours. Some patients may receive mannitol IA over 30 seconds before receiving boron phenylalanine. Patients then undergo planned biopsy of the tumor. Some patients may then undergo immediate surgical debulking of the tumor.

Boron distribution data is analyzed to determine the optimal administration schedule. Patients in stage 2 receives boron phenylalanine via the optimal route established in stage 1. If addition of mannitol is found to be beneficial, then mannitol is used in stage 2

  • Stage 2 (Dose-escalation): Patients receive 1 or 2 doses of boron phenylalanine IV or IA (as determined in stage 1) over 2 hours on day 1. Patients may also receive mannitol IA as in stage 1.

Tumor tissue, normal brain tissue, and cerebrospinal fluid are collected during biopsy and/or surgery. Some patients undergo blood, urine, extracellular fluid sample collection periodically for pharmacokinetic studies. Tumor tissue will be stored for future studies.

After completion of study treatment, patients are followed for 7 days and then once a month.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Being tested
boron phenylalanine, mannitol, biologic sample preservation procedure, radiation therapy treatment planning/simulation
Keywords
adult glioblastoma, adult giant cell glioblastoma, adult gliosarcoma
Medical subject headings
Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • boron phenylalanineDrug

  • mannitolDrug

  • biologic sample preservation procedureOther

  • radiation therapy treatment planning/simulationRadiation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Optimal dose of boron phenylalanine (BPA)

  2. Causality of each adverse event to BPA and grading severity according to NCI CTCAE Version 3.0

  3. Pharmacokinetic (PK) parameters used to construct a PK model with the aim of being able to predict boron up-take by tumor and normal brain tissue

Secondary outcomes (3)
  1. Change in mean dose to the planning target volume of greater than 15%, for a constant maximum and mean dose to normal tissue in any treatment cohort of the study

  2. Change in the intra-nuclear percentage of 10B atoms in any cohort of the study of greater than 20%

  3. Establishment of a repository of samples including serum and tumor tissue for future studies using techniques such as proteomics and DNA array

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2010 (estimated)
  2. Study startOct 2007
  3. Primary completionSep 2013
  4. Study completionSep 2013

Why it stopped: Sponsor Decision

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Masking
None (open label)
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01233492
Sponsor's protocol ID
CDR0000687653
Other IDs
CRUK-PH1/093, EUDRACT-2004-002413-37
Status last verified
Oct 2013
First submitted
2 Nov 2010
Last updated
8 Oct 2013
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing boron phenylalanine, mannitol and biologic sample preservation procedure in people with Brain and Central Nervous System Tumors, run by Cancer Research UK at 2 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 8 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Sponsor Decision). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Optimal dose of boron phenylalanine (BPA). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2013.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT01233492 | AzTrials